Management of Immunotherapy-Induced Diarrhea
Introduction to Racecadotril Use
- The American Society of Clinical Oncology recommends racecadotril for Grade 1 immunotherapy-induced diarrhea in cancer patients as part of symptomatic treatment alongside oral rehydration 1, 2, 3, 4
- Racecadotril is used to treat mild diarrhea (increase of <4 stools per day over baseline) in cancer patients receiving checkpoint inhibitors (anti-CTLA-4 or anti-PD-1 therapy) 4
Treatment Guidelines
- For Grade 1 immunotherapy-induced diarrhea, the European Society for Medical Oncology suggests starting oral rehydration solution and adding racecadotril or loperamide as antidiarrheal 1, 3, 5, 2, 4
- The National Comprehensive Cancer Network recommends continuing immunotherapy in patients with Grade 1 diarrhea 4
- For Grade 2 immunotherapy-induced diarrhea, the American Society of Clinical Oncology advises stopping immunotherapy and considering budesonide 9 mg daily plus symptomatic treatment if there is no bloody diarrhea 1, 5, 3, 4
- For Grade 3-4 immunotherapy-induced diarrhea, the European Society for Medical Oncology recommends avoiding racecadotril, loperamide, and all opioids, and starting IV corticosteroids 1-2 mg/kg/day prednisone equivalent 1, 5, 2, 3, 4
Important Considerations
- The Infectious Diseases Society of America emphasizes the importance of rehydration with oral rehydration solution (or IV fluids if severe dehydration) as the cornerstone of diarrhea management 1, 2, 6, 3, 7
- Close monitoring is required for patients on racecadotril for immunotherapy-induced diarrhea to promptly identify progression to higher grades 4
- Antimotility drugs, including racecadotril, should be avoided in suspected or proven inflammatory diarrhea or diarrhea with fever, as toxic megacolon may result 6
- General antimotility drugs (like loperamide) should not be given to children <18 years with acute diarrhea 6, 7